Company news

Enanta Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4: 30 p.m. ET

August 7, 2022

Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

August 7, 2022

Enanta Pharmaceuticals to Host Conference Call on August 8 at 4: 30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022

July 31, 2022

Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

July 28, 2022

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer

June 20, 2022

Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022

June 7, 2022

Enanta Pharmaceuticals to Participate in Two Investor Conferences in June

June 1, 2022

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

May 17, 2022

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4: 30 p.m. ET

May 8, 2022

Enanta Pharmaceuticals to Host Conference Call on May 9 at 4: 30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022

May 1, 2022

Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

March 28, 2022

Enanta Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

March 7, 2022

Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)

February 16, 2022

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4: 30 p.m. ET

February 7, 2022

Enanta Pharmaceuticals to Host Conference Call on February 8 at 4: 30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2021

January 31, 2022

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4: 30 p.m. ET

November 21, 2021

Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program

November 17, 2021

Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor

November 11, 2021

Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs

October 3, 2021

Enanta Pharmaceuticals Announces Data Presentations at AASLD’s The Liver Meeting® 2021

September 30, 2021

Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors

August 22, 2021

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer

August 15, 2021

Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4: 30 p.m. ET

August 4, 2021

Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

August 4, 2021

Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.

July 13, 2021

Enanta Pharmaceuticals Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic Chronic HBV Patients

June 21, 2021

Enanta Pharmaceuticals Reports Positive Data from Part 2 of its Phase 1b Study of EDP-514 in Chronic Hepatitis B Virus Patients on Treatment with a Nucleoside Reverse Transcriptase Inhibitor

May 5, 2021

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2021 with Webcast and Conference Call Today at 4: 30 p.m. ET

May 5, 2021

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2020 with Webcast and Conference Call Today at 4: 30 p.m. ET

February 7, 2021

Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

January 25, 2021

Enanta Pharmaceuticals Announces the Appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology

January 4, 2021

Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development

December 7, 2020

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020

November 22, 2020

Enanta Pharmaceuticals to Host Conference Call on November 23 at 4: 30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020

November 15, 2020

Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for the Treatment of Non-Alcoholic Steatohepatitis

September 13, 2020

Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2020

August 19, 2020

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2020 with Webcast and Conference Call Today at 4: 30 p.m. ET

August 3, 2020

Enanta Pharmaceuticals to Host Conference Call on August 4 at 4: 30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2020

July 27, 2020

Enanta Pharmaceuticals Announces Clinical Trial Progress for EDP-514, its Lead Core Inhibitor for Hepatitis B Virus

July 8, 2020

Enanta Pharmaceuticals Announces the Appointment of Mark G. Foletta to Its Board of Directors

June 28, 2020

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2020 with Webcast and Conference Call Today at 4: 30 p.m. ET

May 5, 2020

Enanta Announces Results of INTREPID Study of EDP-305 for the Treatment of Primary Biliary Cholangitis

May 5, 2020

Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic

March 25, 2020

Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19

March 12, 2020

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2019

February 5, 2020

Enanta to Host Conference Call on February 6 at 4: 30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2019

January 23, 2020

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

November 20, 2019

Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019

November 10, 2019

New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay

October 2, 2019

Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH

September 24, 2019

← Newer news releases

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.